Supernus Pharmaceuticals News and Activities
Presence
Supernus Pharmaceuticals develops and sells medicines for central nervous system conditions. Its products focus on epilepsy, ADHD, Parkinsons disease, and other neurological disorders for patients, doctors, and healthcare providers.
Supernus Pharmaceuticals products and services overview:
- Neurology medicines
- Epilepsy treatments
- ADHD treatments
- Parkinsons therapies
- CNS drug development
Revenue: ~$662 million
Employees: 630
Headquarters: Rockville, United States (USA)
Supernus Pharmaceuticals is one of the...
Supernus Pharmaceuticals is a company listed under the stock ticker SUPN (US).
Acquisition, funding and merger involving Supernus Pharmaceuticals.
- Supernus Pharmaceuticals has acquired Sage Therapeutics (posted on July 31 2025).
- Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics (posted on June 16 2025).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Supernus Pharmaceuticals
- Jack Khattar, President, Chief Executive Officer and Director
- Carrolee Barlow, Director
- Frederick Hudson, Director
Create your alert
to follow the executive moves at Supernus Pharmaceuticals.
Pharmaceuticals
Supernus Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Supernus Pharmaceuticals
- Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022 | Supernus Pharmaceuticals
- Supernus to Participate in the Jefferies Healthcare Conference | Supernus Pharmaceuticals
- Supernus Announces First Quarter 2022 Financial Results | Supernus Pharmaceuticals
- Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022 | Supernus Pharmaceuticals
- Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults | Supernus Pharmaceuticals
- Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer - Supernus Pharmaceuticals
- Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments - Supernus Pharmaceuticals
- Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference - Supernus Pharmaceuticals
- Supernus to Present at the Wells Fargo Virtual Health Care Conference - Supernus Pharmaceuticals
- Supernus Announces Second Quarter 2020 Financial Results - Supernus Pharmaceuticals
- View more press releases Close
Social media about Supernus Pharmaceuticals
- Supernus Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Supernus Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
